About Shanghai Haoyuan Chemexpress Company

The company was founded in 2006 and focuses on providing small molecule and biomedical industries with life science reagents, drug research and development, process optimization and commercial production of raw materials, intermediates, starting materials and formulations for the global pharmaceutical and biomedical industry. The company has always taken innovation as the core driving force, using the “product+service” model, focusing on differentiated development, and is committed to building an integrated service platform covering drug development and production “starting materials-intermediates-APIs - formulations” to accelerate and empower global partners to achieve the whole process from pre-clinical to commercial production, so that drug development is more efficient, faster to market, and benefits human health earlier. The main business includes research and development of life science reagents in the field of small molecules and novel molecular drug discovery, drug research and development of APIs, intermediates, starting materials and formulations, process optimization, and commercial production. The company has always taken innovation as the core driving force, and has set up business operation hubs in many regions around the world. With a “product+service” model, the company focuses on differentiated development, and is committed to building an integrated service platform covering drug development and production of “starting materials - intermediates - APIs - formulations” to accelerate and empower global partners to achieve efficient transformation of the whole process from pre-clinical to commercial production. The main products are small molecule and new molecular drug raw materials and intermediates. It has won many honorary titles such as “China's Top 50 Pharmaceutical Research and Development”, “China's Top 20 Pharmaceutical CDMO Companies”, and the “First Prize of the Science and Technology Innovation Award” of the China Association for the Promotion of Science and Technology. It has won “China's Top 50 Pharmaceutical Research and Development”, “Top 20 Chinese Pharmaceutical CDMO Companies”, “China's Top 500 New Economy Awards”, “2022 China's Top 500 New Economy Companies”, “2023 Shanghai Top 100 Hard-core Technology Enterprises”, “3rd Pharmaceutical Innovation Ji World Award Selection - Top Ten Pharmaceutical Innovation Service Agencies of the Year”, “China Biomedical Industry Chain Innovation Top 100”, and “2024 Shanghai Top 100 Hard-core Technology Enterprises”.